Recent progress in the development of agonists and antagonists for melatonin receptors.
The various physiological actions of the neurohormone melatonin are mediated mainly by two G-protein-coupled MT(1) and MT(2) receptors. The melatoninergic drugs on the market, ramelteon and agomelatine, as well as the most advanced drug candidates under clinical evaluation, tasimelteon and PD-6735, are high-affinity nonselective MT(1) and MT(2) agonists. However, exploring the exact physiological role of the MT(1) and MT(2) melatonin receptors requires subtype selective MT(1) and MT(2) ligands. This review covers novel melatoninergic agonists and antagonists published since 2010, focusing on high-affinity and subtype selective agents. Additionally, compounds not mentioned in the previous review articles and ligands selective for the MT(3) binding site are included.
The German University in Cairo, Department of Pharmaceutical Chemistry, New Cairo City, 11835 Cairo, Egypt. darius.zlotos@guc.edu.eg
D P
DP
Zlotos
D000081:Acetamides / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D001572:Benzofurans / Q000737:chemistry / Q000494:pharmacology*; D003521:Cyclopropanes / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D007192:Indenes / Q000737:chemistry / Q000494:pharmacology*; D015394:Molecular Structure; D044094:Receptors, Melatonin / Q000819:agonists* / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship; D009281:Naphthalenes
D000081:Acetamides; D001572:Benzofurans; D003521:Cyclopropanes; D007192:Indenes; D044094:Receptors, Melatonin; C084711:agomelatine; D009281:Naphthalenes; C495910:ramelteon; C478745:tasimelteon